195 related articles for article (PubMed ID: 23612147)
1. The negative correlation between thyrotropin receptor-stimulating antibodies and bone mineral density in postmenopausal patients with Graves' disease.
Amashukeli M; Korinteli M; Zerekidze T; Jikurauli N; Shanava S; Tsagareli M; Giorgadze E
J Investig Med; 2013 Jun; 61(5):842-7. PubMed ID: 23612147
[TBL] [Abstract][Full Text] [Related]
2. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
Siderova M; Hristozov K; Tsukeva A
Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
[TBL] [Abstract][Full Text] [Related]
3. Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry.
Wakasugi M; Wakao R; Tawata M; Gan N; Inoue M; Koizumi K; Onaya T
Thyroid; 1994; 4(2):179-82. PubMed ID: 7920000
[TBL] [Abstract][Full Text] [Related]
4. Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves' disease.
Majima T; Komatsu Y; Doi K; Takagi C; Shigemoto M; Fukao A; Morimoto T; Corners J; Nakao K
Osteoporos Int; 2006; 17(7):1103-10. PubMed ID: 16601919
[TBL] [Abstract][Full Text] [Related]
5. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
6. The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves' Disease.
Cho SW; Bae JH; Noh GW; Kim YA; Moon MK; Park KU; Song J; Yi KH; Park do J; Chung JK; Cho BY; Park YJ
PLoS One; 2015; 10(12):e0144599. PubMed ID: 26650844
[TBL] [Abstract][Full Text] [Related]
7. The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women.
Baqi L; Payer J; Killinger Z; Susienkova K; Jackuliak P; Cierny D; Langer P
Endocr Regul; 2010 Jan; 44(1):9-15. PubMed ID: 20151763
[TBL] [Abstract][Full Text] [Related]
8. Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease.
Ercolano MA; Drnovsek ML; Silva Croome MC; Moos M; Fuentes AM; Viale F; Feldt-Rasmussen U; Gauna AT
Thyroid Res; 2013 Sep; 6(1):11. PubMed ID: 24020400
[TBL] [Abstract][Full Text] [Related]
9. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication.
Smith J; Brown RS
Thyroid; 2007 Nov; 17(11):1103-7. PubMed ID: 17822376
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
11. Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease.
Lucidarme N; Ruiz JC; Czernichow P; Léger J
J Pediatr; 2000 Jul; 137(1):56-62. PubMed ID: 10891822
[TBL] [Abstract][Full Text] [Related]
12. [The latest progress in the pathogenesis and diagnosis of Graves' disease].
Kimura T; Okamoto Y
Nihon Rinsho; 2012 Nov; 70(11):1908-12. PubMed ID: 23214060
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density after surgical treatment for Graves' disease.
Arata N; Momotani N; Maruyama H; Saruta T; Tsukatani K; Kubo A; Ikemoto K; Ito K
Thyroid; 1997 Aug; 7(4):547-54. PubMed ID: 9292941
[TBL] [Abstract][Full Text] [Related]
14. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y
Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915
[TBL] [Abstract][Full Text] [Related]
15. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
16. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
17. Direct binding of thyrotropin receptor autoantibody to in vitro translated thyrotropin receptor: a comparison to radioreceptor assay and thyroid stimulating bioassay.
Morgenthaler NG; Hodak K; Seissler J; Steinbrenner H; Pampel I; Gupta M; McGregor AM; Scherbaum WA; Banga JP
Thyroid; 1999 May; 9(5):466-75. PubMed ID: 10365678
[TBL] [Abstract][Full Text] [Related]
18. The role of TSH receptor antibodies in the management of Graves' disease.
Matthews DC; Syed AA
Eur J Intern Med; 2011 Jun; 22(3):213-6. PubMed ID: 21570635
[TBL] [Abstract][Full Text] [Related]
19. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
Morgenthaler NG; Ho SC; Minich WB
J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
[TBL] [Abstract][Full Text] [Related]
20. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Fiore E; Bucci I; Chamblin T; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1106-15. PubMed ID: 22496495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
